Completing a Pneumococcal Conjugate Vaccine Series

<table>
<thead>
<tr>
<th>Age at Presentation for Immunization</th>
<th>History of Prior Doses of PCV7, PCV10, or PCV13 Given</th>
<th>Completion of a Series Requires</th>
<th>Booster Dose Healthy and High Risk B</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Healthy Infant</td>
<td>High Risk Infant A, B</td>
</tr>
<tr>
<td>3-11 months</td>
<td>0 doses</td>
<td>2 doses C</td>
<td>3 doses C</td>
</tr>
<tr>
<td></td>
<td>1 dose</td>
<td>1 dose C</td>
<td>2 doses C</td>
</tr>
<tr>
<td></td>
<td>2 doses</td>
<td>0 doses</td>
<td>1 dose D</td>
</tr>
<tr>
<td>12-23 months</td>
<td>0 doses</td>
<td>2 doses E</td>
<td>2 doses E</td>
</tr>
<tr>
<td></td>
<td>1 dose &lt; 12 months</td>
<td>2 doses E</td>
<td>2 doses E</td>
</tr>
<tr>
<td></td>
<td>1 dose ≥ 12 months</td>
<td>1 dose E</td>
<td>1 dose E</td>
</tr>
<tr>
<td></td>
<td>2 doses &lt; 12 months</td>
<td>1 dose D</td>
<td>1 dose E</td>
</tr>
<tr>
<td></td>
<td>1 dose &lt; 12 months &amp; 1 dose ≥ 12 months</td>
<td>1 dose E</td>
<td>1 dose E</td>
</tr>
<tr>
<td>24-59 months</td>
<td>0 doses</td>
<td>1 dose</td>
<td>1 dose</td>
</tr>
<tr>
<td></td>
<td>Any age-appropriate series incomplete by 24 months</td>
<td>1 dose E</td>
<td>1 dose E</td>
</tr>
<tr>
<td></td>
<td>Complete PCV7 or PCV10 series F</td>
<td>0 doses</td>
<td>1 dose E</td>
</tr>
</tbody>
</table>

A When an infant has received 1 or 2 doses of vaccine, and is subsequently diagnosed with a medical condition putting them at high risk of pneumococcal disease, use the table to complete the PCV series as “high risk”. When a high risk condition is diagnosed after completion of a PCV series, no further doses are recommended, except for specific conditions outlined in Part 2 – Immunization of Special Populations (e.g., HSCT recipients).

B Children at high risk of pneumococcal disease due to an underlying medical condition should receive 1 dose of pneumococcal polysaccharide vaccine at 2 years of age, and at least 8 weeks after their final pneumococcal conjugate vaccine dose.

C The recommended interval between doses is 8 weeks. However, the minimum interval of 4 weeks may be considered. See Part 1 – Immunization Schedules, Minimum Intervals Between Vaccine Doses.

D At least 8 weeks after the previous dose.

E 8 weeks between doses.

F A complete series is:
- 2 (PVC7) or 3 (PVC7 [high risk] or PCV10) primary doses given at appropriate intervals and a 3rd or 4th dose given on or after 12 months of age and at least 8 weeks after previous dose, or
- a delayed or interrupted schedule that has been completed at a later age according to the information in this table.